Asia-Pacific Indapamide Market
Asia-Pacific Indapamide Market Size, Share & Trends Analysis By Product Type (Immediate-Release Tablets, Sustained/Extended-Release Tablets), By Strength (1.25 mg, 2.5 mg, Other Customized Dosages), By Application (Hypertension, Edema, Heart Failure), Forecast Period (2026-2035)
Industry Overview
Asia-Pacific indapamide market was valued at $46.5 million in 2025 and is projected to reach $61.4 million by 2035, growing at a CAGR of 2.8% from 2026 to 2035. The Asia-Pacific indapamide market is supported by the continuing requirement for pharmacological management of hypertension and related cardiovascular conditions. Persistent gaps in blood-pressure diagnosis, treatment and control across several regional countries sustain demand for established antihypertensive therapies. Indapamide remains relevant as a thiazide-like diuretic and is used both as a standalone therapy and in fixed-dose combinations with other antihypertensive agents. The availability of generic formulations has broadened access while maintaining competition among domestic and international pharmaceutical manufacturers. Sustained-release formulations and combination products are also strengthening the role of indapamide within long-term hypertension treatment. Regulatory support for established medicines and expanding chronic-care infrastructure further contribute to regional demand.
Market Dynamics
Increasing Use of Combination Antihypertensive Therapy
A notable trend in the Asia-Pacific indapamide market is the continued development and use of combination antihypertensive formulations. Indapamide is increasingly positioned alongside agents such as perindopril, amlodipine, telmisartan, atenolol, and other cardiovascular medicines. This approach supports treatment regimens where blood pressure is not adequately controlled through a single medicine and can simplify medication schedules. China's revised hypertension guidance specifically identifies indapamide among commonly used thiazide diuretics and supports low-dose thiazide combinations with renin-angiotensin system inhibitors. Regional product portfolios similarly show extensive development of indapamide-based combinations.
Expansion of Generic and Sustained-Release Formulations
Generic competition and sustained-release formulations remain important features of the regional market. Multiple Asian manufacturers supply conventional and modified-release indapamide products, while Australia has several registered formulations from different suppliers. Sustained-release products provide a once-daily formulation option and continue to form an important part of established hypertension portfolios. Regulatory registrations also allow additional generic suppliers to enter or maintain participation in individual national markets. This creates a competitive environment in which established branded products coexist with lower-cost generic alternatives.
Market Segmentation
- Based on the product type, the market is segmented into immediate-release (IR) tablets and sustained/extended-release (SR/ER) tablets.
- Based on the strength, the market is segmented into 1.25 mg, 2.5 mg, and other customized dosages.
- Based on the application, the market is segmented into hypertension, edema, and heart failure.
1.25 MG Segment to Lead the Market with the Largest Share
The 1.25 MG segment has a strong position because lower-dose indapamide formulations are widely incorporated into sustained-release and combination antihypertensive therapies. Regional product evidence includes 1.25 mg formulations and combinations with perindopril, while Australian pharmaceutical listings also recognize indapamide-containing products at this strength. The segment benefits from its suitability within long-term blood-pressure management and fixed-dose combination regimens.
High Blood Pressure: A Key Segment in Market Growth
High Blood Pressure represents the principal application for indapamide across Asia-Pacific. The medicine is established as an antihypertensive treatment, while national and international clinical guidance continues to recognize diuretic therapy as part of blood-pressure management. China's current hypertension guidance specifically includes indapamide among commonly used thiazide diuretics, while Indian and WHO sources identify hypertension control as an ongoing healthcare priority. The continuing treatment gap therefore provides a sustained demand base for established antihypertensive medicines.
Regional Outlook
The Asia-Pacific indapamide market is further divided by countries, including India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific.
India to Witness as a Fastest Growing Region
India represents a major market for indapamide within Asia-Pacific because of its large hypertension burden, extensive domestic pharmaceutical manufacturing base, and broad availability of indapamide-containing products. Domestic companies supply standalone indapamide as well as combinations with amlodipine, perindopril, atenolol and other cardiovascular medicines. Product listings identify numerous Indian manufacturers and marketers, while companies such as Torrent, Zydus, Glenmark, Sun Pharmaceutical Industries, Lupin and other domestic manufacturers have established cardiovascular portfolios. India's national hypertension-control programs are also expanding systematic screening, treatment and follow-up, supporting continued demand for established antihypertensive medicines.
Market Players Outlook
The major companies operating in the Asia-Pacific indapamide market include Servier Group, Torrent Pharmaceuticals Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, and Sandoz International GmbH, among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
- In September 2026, Australia's Therapeutic Goods Administration approved Coveram Plus SR, a new combination containing perindopril arginine, amlodipine and indapamide. The product was approved for substitution therapy in patients whose hypertension was already controlled with the same three active ingredients.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the Asia-Pacific indapamide market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Asia-Pacific Indapamide Market Sales Analysis – Product Type | Strength | Application ($ Million)
- Indapamide Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Indapamide Industry Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Indapamide Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Asia-Pacific Indapamide Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Asia-Pacific Indapamide Market: Impact Analysis
- Market Opportunities
- Opportunities For Asia-Pacific Indapamide Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Indapamide Market Revenue and Share by Manufacturers
- Indapamide Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Glenmark Pharmaceuticals Limited
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Sandoz International GmbH
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Servier Group
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Torrent Pharmaceuticals Limited
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Zydus Lifesciences Limited
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Glenmark Pharmaceuticals Limited
- Key Company Analysis
- Asia-Pacific Indapamide Market Sales Analysis by Product Type ($ Million)
- Immediate-Release (IR) Tablets
- Sustained/Extended-Release (SR/ER) Tablets
- Asia-Pacific Indapamide Market Sales Analysis by Strength ($ Million)
- 25 mg
- 5 mg
- Other Customized Dosages
- Asia-Pacific Indapamide Market Sales Analysis by Application ($ Million)
- Hypertension
- Edema (Fluid Retention)
- Heart Failure (Adjunct Therapy)
- Regional Analysis
- Asia-Pacific Indapamide Market Sales Analysis – Product Type | Strength | Application | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Others)
- Rest of Asia-Pacific
- Company Profiles
- Alphapharm Pty Ltd
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Apotex Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Arrotex Pharmaceuticals Pty Ltd
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bal Pharma Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cadila Pharmaceuticals Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cipla Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Glenmark Pharmaceuticals Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ipca Laboratories Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Kyoto Pharmaceutical Industries, Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lotus Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lupin Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Macleods Pharmaceuticals Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Mankind Pharma Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Micro Labs Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Modi-Mundipharma Private Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Orchid Chemicals & Pharmaceuticals Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sandoz International GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Servier Group
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Shandong Yinfeida Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Torrent Pharmaceuticals Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- USV Private Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Yung Shin Pharmaceutical Industrial Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zydus Lifesciences Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Alphapharm Pty Ltd
1. Asia-Pacific Indapamide Market Research and Analysis by Product Type, 2025–2035 ($ Million)
2. Asia-Pacific Immediate-Release (IR) Tablets Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Asia-Pacific Sustained/Extended-Release (SR/ER) Tablets Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Asia-Pacific Indapamide Market Research and Analysis by Strength, 2025–2035 ($ Million)
5. Asia-Pacific 1.25 mg Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Asia-Pacific 2.5 mg Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Asia-Pacific Other Customized Dosages Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Asia-Pacific Indapamide Market Research and Analysis by Application, 2025–2035 ($ Million)
9. Asia-Pacific Indapamide for Hypertension Research and Analysis by Region, 2025–2035 ($ Million)
10. Asia-Pacific Indapamide for Edema (Fluid Retention) Research and Analysis by Region, 2025–2035 ($ Million)
11. Asia-Pacific Indapamide for Heart Failure (Adjunct Therapy) Research and Analysis by Region, 2025–2035 ($ Million)
12. Asia-Pacific Indapamide Market Research And Analysis By Geography, 2025-2035 ($ Million)
13. North American Indapamide Market Research And Analysis By Country, 2025-2035 ($ Million)
14. North American Indapamide Market Research And Analysis By Product Type, 2025-2035 ($ Million)
15. North American Indapamide Market Research And Analysis By Strength, 2025-2035 ($ Million)
16. North American Indapamide Market Research And Analysis By Application, 2025-2035 ($ Million)
17. European Indapamide Market Research And Analysis By Country, 2025-2035 ($ Million)
18. European Indapamide Market Research And Analysis By Product Type, 2025-2035 ($ Million)
19. European Indapamide Market Research And Analysis By Strength, 2025-2035 ($ Million)
20. European Indapamide Market Research And Analysis By Application, 2025-2035 ($ Million)
21. Asia-Pacific Indapamide Market Research And Analysis By Country, 2025-2035 ($ Million)
22. Asia-Pacific Indapamide Market Research And Analysis By Product Type, 2025-2035 ($ Million)
23. Asia-Pacific Indapamide Market Research And Analysis By Strength, 2025-2035 ($ Million)
24. Asia-Pacific Indapamide Market Research And Analysis By Application, 2025-2035 ($ Million)
25. Rest Of The World Indapamide Market Research And Analysis By Country, 2025-2035 ($ Million)
26. Rest Of The World Indapamide Market Research And Analysis By Product Type, 2025-2035 ($ Million)
27. Rest Of The World Indapamide Market Research And Analysis By Strength, 2025-2035 ($ Million)
28. Rest Of The World Indapamide Market Research And Analysis By Application, 2025-2035 ($ Million)
1. Asia-Pacific Indapamide Market Share by Product Type, 2025 vs 2035 (%)
2. Asia-Pacific Immediate-Release (IR) Tablets Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
3. Asia-Pacific Sustained/Extended-Release (SR/ER) Tablets Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
4. Asia-Pacific Indapamide Market Share by Strength, 2025 vs 2035 (%)
5. Asia-Pacific 1.25 mg Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
6. Asia-Pacific 2.5 mg Indapamide Market Research and Analysis by Region, 2025 vs 2035 (%)
7. Asia-Pacific Other Customized Dosages Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
8. Asia-Pacific Indapamide Market Share by Application, 2025 vs 2035 (%)
9. Asia-Pacific Indapamide for Hypertension Market Research and Analysis by Region, 2025 vs 2035 (%)
10. Asia-Pacific Indapamide for Edema (Fluid Retention) Market Research and Analysis by Region, 2025 Vs 2035 (%)
11. Asia-Pacific Indapamide for Heart Failure (Adjunct Therapy) Market Research and Analysis by Region, 2025 Vs 2035 (%)
12. Asia-Pacific Indapamide Market Share By Region, 2025 Vs 2035 (%)
13. US Indapamide Market Size, 2025-2035 ($ Million)
14. Canada Indapamide Market Size, 2025-2035 ($ Million)
15. UK Indapamide Market Size, 2025-2035 ($ Million)
16. France Indapamide Market Size, 2025-2035 ($ Million)
17. Germany Indapamide Market Size, 2025-2035 ($ Million)
18. Italy Indapamide Market Size, 2025-2035 ($ Million)
19. Spain Indapamide Market Size, 2025-2035 ($ Million)
20. Russia Indapamide Market Size, 2025-2035 ($ Million)
21. Rest Of Europe Indapamide Market Size, 2025-2035 ($ Million)
22. India Indapamide Market Size, 2025-2035 ($ Million)
23. China Indapamide Market Size, 2025-2035 ($ Million)
24. Japan Indapamide Market Size, 2025-2035 ($ Million)
25. South Korea Indapamide Market Size, 2025-2035 ($ Million)
26. ASEAN Indapamide Market Size, 2025-2035 ($ Million)
27. Australia and New Zealand Indapamide Market Size, 2025-2035 ($ Million)
28. Rest Of Asia-Pacific Indapamide Market Size, 2025-2035 ($ Million)
29. Latin America Indapamide Market Size, 2025-2035 ($ Million)
30. Middle East And Africa Indapamide Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of users within the company
